AMT-562
AMT-562 is an antibody-drug conjugate (ADC) consisting of a novel anti-HER3 antibody Ab562 conjugated to the linker MC-VA-PAB and the topoisomerase I inhibitor Exatecan (HY-13631). The ADC toxic molecule and linker portion are MC-VA-PAB-Exatecan (HY-147270). AMT-562 can induce apoptosis and has antitumor activity against pancreatic, esophageal, and gastric cancers[1][2].
Product Specifications
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; Apoptosis; EGFR; Topoisomerase
Related Pathways
Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
[AMT-562]
References & Citations
[1]Weng W, et al. AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors. Mol Cancer Ther. 2023 Sep 5;22 (9) :1013-1027. |[2]KRAIEM, et al. Treatment of cancer. WO2021151984A1.
Shipping Conditions
Room temperature
Scientific Category
ADC Related
Clinical Information
No Development Reported
Isoform
ErbB3/HER3; Topo I
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
